EyePoint's DURAVYU Phase 3 LUGANO Trial Misses Primary Endpoint; Stock Plunges
EyePoint (EYPT) reported topline Phase 3 LUGANO results for DURAVYU (vorolanib intravitreal insert) in wet AMD. The trial missed the primary endpoint versus aflibercept in the full dataset, but an ad hoc analysis excluding a small cohort showed non-inferiority (p=0.0096). Secondary results included a 42% treatment-burden reduction (p<0.0001). LUCIA data expected Q4 2026.
How this was made
The 30-second read
Why it matters
The LUGANO topline miss on the primary BCVA endpoint versus aflibercept control is a direct negative catalyst, but the company points to strong secondary endpoints and an ad hoc non-inferiority result as support for continued development and an NDA plan.
Market read
Traders are likely to reprice EYPT on the immediate Phase 3 primary endpoint miss, while monitoring whether LUCIA can provide supportive evidence for an NDA in 1H 2027.
What to watch
The article highlights treatment-burden reduction and supplement-free rates, which could matter to payers and clinicians even if the primary BCVA comparison was not met.
Background
DURAVYU (vorolanib intravitreal insert) is EyePoint’s sustained-release investigational therapy for wet age-related macular degeneration, evaluated in two pivotal Phase 3 trials (LUGANO and LUCIA).
Ticker impact
EyePoint reported LUGANO Phase 3 topline results for DURAVYU, missing the primary BCVA endpoint versus aflibercept control.
Near-term downside pressure likely persists on the primary endpoint miss, with volatility around LUCIA readout timing and NDA-supportive evidence.
The article discloses a clear Phase 3 primary endpoint miss plus specific secondary benefits and a planned NDA timeline, which typically drives immediate repricing while leaving a contingent upside scenario.
Market effects
Wet AMD and intravitreal sustained-release development programs may see sentiment pressure after a pivotal trial primary endpoint miss, even with secondary benefits.
US small/mid-cap biotech sentiment likely negative given the reported pre-market collapse.
Could influence competitive positioning and investor expectations for other wet AMD sustained-release approaches ahead of their pivotal readouts.
Counterpoint
The primary endpoint miss is partially explained by an asymmetric cohort; the ad hoc analysis shows non-inferiority with statistically significant secondary outcomes, which may reduce the perceived regulatory risk.
Key entities
- companyEyePoint, Inc.
Sponsor of DURAVYU and reporter of LUGANO Phase 3 topline results.
- productDURAVYU (vorolanib intravitreal insert)
Sustained-release investigational therapy for wet AMD intended to reduce injection frequency.
- clinical_trialLUGANO trial
First of two pivotal Phase 3 trials; topline results missed the primary endpoint.
- comparatoraflibercept (EYLEA)
On-label control used for the primary endpoint comparison in LUGANO.
- clinical_trialLUCIA trial
Second pivotal Phase 3 trial; topline data expected in Q4 2026.
